Lung disease | Fujirebio

A selection of insight articles on the topic of lung disease biomarkers:

This scientific literature overview demonstrates the excellent performance of the fully automated nucleocapsid protein antigen assay Lumipulse® G SARS-CoV-2 Ag

Lumipulse G SARS-CoV-2 Ag was the first high-sensitive nucleocapsid protein antigen assay launched on a fully automated chemiluminescent platform.

...

May 27, 2021

Lung disease

Large-scale and fully automated COVID-19 antigen testing for travelers in German airports

Since November 2020 Fujirebio Europe and CENTOGENE have partnered to leverage LUMIPULSE® G technology for large-scale COVID-19 antigen testing in...

May 11, 2021

Lung disease

Webinar: Lumipulse® G KL-6, the biomarker for routinely assessment of epithelial alveolar damage in pulmonary fibrosis and COVID-19

During this webinar Dr. Francesco Bonella (MD - Center for Interstitial & Rare Lung Disease, Department of Pulmonology, Ruhrlandklinik University...

Oct 19, 2020

COVID-19 antigen testing in Haneda airport in Tokyo Japan

Lung disease

Japanese authorities have chosen Lumipulse® for nasopharyngeal or saliva-based SARS-CoV-2 antigen testing of passengers at their main international airports

Several fully automated and CLEIA-based LUMIPULSE G1200 systems from Fujirebio are right now performing fast, high sensitivity SARS CoV-2 antigen...

Aug 26, 2020

Lung disease

Can KL-6 be a specific marker of alveolar damage for COVID-19 patients?

There are many reference centers across Europe that have included KL-6 as one of the biomarkers within the COVID-19 protocol to strengthen the battery...

Apr 30, 2020

Lung disease

From Classification to disease activity

While IPF is the classic fibrosing ILD, clinical data suggest that there is a larger group of patients with differing clinical ILD diagnoses who...

Dec 17, 2019

Lung disease

KL-6 in disease prognosis

Recent research has shown that serum and bronchoalveolar lavage fluid level of KL-6 has an important value in the diagnosis, treatment assessment and...

Dec 2, 2019

Lung disease

Use of serum biomarkers in progressive fibrosing ILDs

Based on the results from a number of reports investigating KL-6/MUC1, the serum levels of KL-6/MUC1 are useful for 1) detecting the presence of...

Nov 18, 2019

Lung disease

ILD diagnosis – current professional practice

Accurate diagnosis of IPF is critical, as other forms of ILD that have similar clinical presentations to IPF require different treatment strategies.

Nov 5, 2019

Lung disease

KL-6 in Lung Diseases: Current classification of interstitial lung diseases

Interstitial lung diseases (ILDs) represent a large, heterogeneous group of more than 200 different entities, most of which are classified as rare...

Oct 24, 2019

Lung disease

Mesothelin, the novel, non-invasive in vitro biomarker to aid in the diagnosis of Mesothelioma

Mesothelioma is a rare form of cancer that is linked to exposure to asbestos. Although malignant mesothelioma remains a relatively uncommon malignancy...

Jun 6, 2019

ESPLINE^® SARS-CoV-2

Product number 231906 -

Immunochromatographic assay for the detection of SARS-CoV-2 antigen directly from nasopharyngeal swab fluid and is intended for use as an aid in the diagnosis of SARS-CoV-2 infection.

CE marked

Detail

iAMP COVID-19 Detection Kit

Product number 80767, 80762 -

Qualitative nucleic acid detection of SARS-CoV-2 (COVID-19) on naso- or oropharyngeal swabs without pre-treatment.

CE marked

Detail

iAMP COVID-19 SANO Assay

Product number 81104, 80762, 80812 -

Qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal swabs and saliva specimens from individuals with signs and symptoms of infection who are suspected of COVID-19.

CE marked

Detail

Lumipulse^® G CEA-N (Carcinoembryonic Antigen)

Product number 292662 -

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of carcinoembryonic antigen (CEA) in serum or plasma.

CE marked

Detail

Lumipulse^® G CYFRA (Cytokeratin Subunit 19 Fragment)

Product number 292945 -

Immunoreaction cartridges for in vitro diagnostic use with the LUMIPULSE G System for the quantitative measurement of cytokeratin subunit 19 fragment (CYFRA) in serum or plasma.

CE marked

Detail

Lumipulse^® G KL-6 (Krebs von den Lungen)

Product number 233207 -

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of sialylated carbohydrate antigen, KL-6 in serum or plasma.

CE marked

Detail

Lumipulse^® G Mesothelin

Product number 294192 -

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative determination Soluble Mesothelin Related Peptides (SMRP) in human serum or plasma.

CE marked

Detail

Lumipulse^® G ProGRP (Pro-Gastrin-Releasing Peptide)

Product number 297858 -

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of Pro-gastrin-releasing peptide [ProGRP (31-98)] in serum or plasma.

CE marked

Detail

Lumipulse^® G SARS-CoV-2 Ag

Product number 260340, 231869 -

For in vitro diagnostic (IVD) use with the Lumipulse G system for detection and quantitative measurement of SARS-CoV-2 nucleocapsid protein antigen in human nasopharyngeal swab or saliva. As a diagnostic tool for the confirmation of a SARS-CoV-2 infection.

CE marked

Detail

Lumipulse^® G SARS-CoV-2 N-IgG

Product number 232323 -

For in vitro diagnostic (IVD) use with the Lumipulse G system for the quantitative measurement of IgG antibodies to SARS-CoV-2 nucleocapsid (N) protein in human serum or plasma. SARS-CoV-2 N antibody measurement is intended to be used as an aid in the assessment of immune response to the SARS-CoV-2 N protein.

CE marked

Detail

Lumipulse^® G SARS-CoV-2 N-IgG Controls

Product number 232354 -

For in vitro diagnostic (IVD) use as quality controls, to monitor the precision and accuracy of the Lumipulse G SARS-CoV-2 N-IgG assay on the automated LUMIPULSE G System.

CE marked

Detail

Lumipulse^® G SARS-CoV-2 S-IgG

Product number 232231 -

For in vitro diagnostic (IVD) use with the Lumipulse G system for the quantitative measurement of IgG-type antibodies SARS-CoV-2 spike protein (SARS-CoV-2 S-IgG) in specimens based on CLEIA technology by a specific two-step immunoassay method on the LUMIPULSE G System.

CE marked

Detail

Lumipulse^® G SCC (Squamous Cell Carcinoma)

Product number 298411, 235430 -

Immunoreaction cartridges for in vitro diagnostic use with the LUMIPULSE G instruments for the quantitative measurement of squamous cell carcinoma (SCC) antigen in human serum or plasma samples as an aid in the management of patients with squamous cell carcinoma.

CE marked

Detail

Lumipulse^® SARS-CoV-2 Ag Controls

Product number 231876 -

These controls are intended for use as an assayed quality control material to monitor the precision of laboratory testing procedures for the analysis of SARS-CoV-2 antigen on the LUMIPULSE G System.

CE marked

Detail

A selection of insight articles on the topic of lung disease biomarkers:

Related products